908 Devices (NASDAQ:MASS) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a report published on Saturday morning,Weiss Ratings reports.

A number of other equities analysts have also recently weighed in on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research note on Wednesday. Stifel Nicolaus dropped their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Leerink Partnrs lowered 908 Devices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Trading Up 2.8 %

MASS stock traded up $0.08 during midday trading on Friday, hitting $2.98. 1,347,475 shares of the company’s stock were exchanged, compared to its average volume of 369,045. The business has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $3.50. 908 Devices has a 1-year low of $1.81 and a 1-year high of $8.50. The stock has a market capitalization of $103.76 million, a PE ratio of -1.68 and a beta of 0.96.

Hedge Funds Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC grew its stake in shares of 908 Devices by 35.5% during the second quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock worth $3,184,000 after purchasing an additional 161,922 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of 908 Devices by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock worth $1,970,000 after acquiring an additional 6,634 shares in the last quarter. State Street Corp raised its position in shares of 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after acquiring an additional 5,704 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in 908 Devices by 88.3% during the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock worth $1,263,000 after purchasing an additional 114,987 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in 908 Devices by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after purchasing an additional 28,015 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.